Posted by Michael Wonder on 28 Jun 2023
Verona Pharma submits new drug application to US FDA for ensifentrine for the maintenance treatment of COPD
27 June 2023 - Verona Pharma announces the submission of a new drug application to the US FDA for approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease.
Ensifentrine is a selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and non-steroidal anti-inflammatory activities in one molecule.
